Methotrexate Aspire Pharma (Malta)

Methotrexate, the active ingredient in Methotrexate Aspire Pharma (Malta), is an antimetabolite (folate antagonist) presented as an oral dosage form for oral use. It is employed to treat autoimmune disorders, certain cancers, and ectopic pregnancy in appropriate patient populations.

GNH USA supplies Methotrexate Aspire Pharma (Malta) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate acts as a disease‑modifying agent across several therapeutic areas: - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Non‑Hodgkin lymphoma: impedes growth of lymphoma cells. - Ectopic pregnancy: terminates trophoblastic tissue when surgery is not indicated.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting. - Oral ulcers or mucositis. - Fatigue or malaise. - Elevated liver enzymes. - Mild bone marrow suppression (e.g., low white blood cells). - Skin rash or photosensitivity.

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis. - Significant bone marrow failure (e.g., pancytopenia). - Pulmonary toxicity (interstitial pneumonitis). - Renal impairment or failure. - Severe cutaneous adverse reactions (e.g., Stevens‑Johnson syndrome).

Methotrexate requires careful monitoring and patient education. - Pregnancy: contraindicated; teratogenic risk is classified as Category X. - Liver function: assess baseline enzymes and monitor regularly. - Renal function: adjust dose in patients with impaired clearance. - Hematology: perform routine blood counts to detect marrow suppression. - Drug interactions: avoid concurrent use of nephrotoxic or hepatotoxic agents. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Methotrexate may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Proton pump inhibitors (e.g., omeprazole): may raise plasma levels. - Trimethoprim‑sulfamethoxazole: heightens risk of bone marrow suppression.

Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: additive myelosuppression. - Live vaccines: risk of infection due to immunosuppression. - Alcohol: exacerbates hepatotoxic potential.